Ubs Group Ag Acelrx Pharmaceuticals Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$0.2 - $0.35 $10,607 - $18,562
53,036 Added 982.15%
58,436 $12,000
Q2 2022

Aug 10, 2022
BUY
$0.18 - $0.29 $900 - $1,450
5,000 Added 1250.0%
5,400 $1,000
Q1 2022

May 16, 2022
SELL
$0.28 - $0.61 $19,978 - $43,524
-71,352 Reduced 99.44%
400 $0
Q4 2021

Feb 14, 2022
BUY
$0.49 - $1.02 $35,011 - $72,881
71,452 Added 23817.33%
71,752 $40,000
Q3 2021

Nov 15, 2021
SELL
$0.93 - $1.51 $36,537 - $59,324
-39,288 Reduced 99.24%
300 $0
Q2 2021

Aug 13, 2021
BUY
$1.03 - $1.7 $1,451 - $2,395
1,409 Added 3.69%
39,588 $54,000
Q1 2021

May 12, 2021
SELL
$1.25 - $2.77 $3,082 - $6,830
-2,466 Reduced 6.07%
38,179 $65,000
Q4 2020

Feb 11, 2021
BUY
$1.18 - $1.98 $9,999 - $16,778
8,474 Added 26.34%
40,645 $50,000
Q3 2020

Nov 12, 2020
SELL
$1.01 - $1.81 $5,268 - $9,440
-5,216 Reduced 13.95%
32,171 $45,000
Q2 2020

Jul 31, 2020
SELL
$1.03 - $1.69 $24,782 - $40,663
-24,061 Reduced 39.16%
37,387 $46,000
Q1 2020

May 01, 2020
SELL
$0.76 - $2.07 $49,637 - $135,195
-65,312 Reduced 51.52%
61,448 $73,000
Q4 2019

Feb 14, 2020
BUY
$1.66 - $2.4 $77,937 - $112,680
46,950 Added 58.83%
126,760 $267,000
Q3 2019

Nov 14, 2019
BUY
$2.1 - $2.87 $65,310 - $89,257
31,100 Added 63.85%
79,810 $176,000
Q2 2019

Aug 14, 2019
BUY
$2.1 - $3.93 $9,011 - $16,863
4,291 Added 9.66%
48,710 $124,000
Q1 2019

May 14, 2019
SELL
$2.35 - $3.83 $40,420 - $65,876
-17,200 Reduced 27.91%
44,419 $154,000
Q4 2018

Feb 14, 2019
BUY
$2.13 - $4.8 $117,588 - $264,988
55,206 Added 860.85%
61,619 $142,000
Q3 2018

Nov 14, 2018
BUY
$2.6 - $4.6 $14,073 - $24,899
5,413 Added 541.3%
6,413 $25,000
Q1 2018

May 15, 2018
SELL
$1.7 - $2.35 $2,475 - $3,421
-1,456 Reduced 59.28%
1,000 $2,000
Q4 2017

Feb 14, 2018
BUY
$1.75 - $5.5 $2,548 - $8,008
1,456 Added 145.6%
2,456 $5,000
Q3 2017

Nov 14, 2017
SELL
$2.9 - $4.6 $18,156 - $28,800
-6,261 Reduced 86.23%
1,000 $5,000
Q2 2017

Aug 14, 2017
BUY
N/A
3,988 Added 121.85%
7,261 $15,000
Q1 2017

Nov 14, 2017
BUY
N/A
3,273
3,273 $10,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email